Companies › Ascletis Pharma (China)
3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Metabolic and endocrine; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ASC30 | – | Phase 3 | Obesity | Jul 2028 |
| ASC36 Injection GLP-1 receptor agonist | – | Phase 1 | Chronic Weight Management | Apr 2027 |
| ASC35 Injection B Dual GLP-1/GIP receptor agonist | – | Phase 1 | Chronic Weight Management | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07893106 | ASC36 Injection | Phase 1 | Chronic Weight Management | Metabolic and endocrine | Apr 2027 |
| NCT07893093 | ASC36 Injection | Phase 1 | Chronic Weight Management | Metabolic and endocrine | Jun 2027 |
| NCT07842640 | ASC35 Injection B | Phase 1 | Chronic Weight Management | Metabolic and endocrine | Jun 2027 |
| NCT07743463 | ASC30 | Phase 3 | Obesity | Metabolic and endocrine | Jul 2028 |
| NCT07743450 | ASC30 | Phase 3 | Obesity | Metabolic and endocrine | Jul 2028 |
No annotated target.
–
The United Bio-Technology (Hengqin) JCR Pharmaceuticals Innovent Biologics Technology Limited (Shanghai R&D Center) Laekna Viking Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.